News

VaLogic Bio Acquires Facility Logix to Expand Life Sciences Facility Services

VaLogic Bio, a platform company of 424 Capital and a leading provider of compliance and SaaS services to the life sciences industry, proudly announces the acquisition of Facility Logix (FLGX), a renowned firm specializing in planning, developing, and project management for life sciences facilities. This acquisition aligns with VaLogic Bio’s strategic vision to enhance its capabilities and broaden its footprint in the life sciences sector.

With this acquisition, VaLogic Bio will leverage Facility Logix’s current service offerings to build a market-leading, full-service outsourced solutions platform. This platform aims to enable life science and biotechnology companies to remain GMP compliant through advisory, project management, procurement, technical equipment servicing, facility design/engineering and construction, environmental monitoring, and CQV services. These services will help clients run their labs and manufacturing suites more efficiently, allowing them to focus on advancing life-saving therapeutics. The combined company provides clients an unparalleled suite of services, from initial facility concept to operational readiness and ongoing compliance.

As part of the acquisition, Pat Larrabee, formerly the CEO and founder of Facility Logix, will become the Vice President of Advisory Services and join the VaLogic Bio leadership team.

The former Facility Logix team will continue to operate out of its Montgomery County, Maryland office in Burtonsville. With its proven track record, the team will continue to deliver high-quality, conflict-free services, ensuring a seamless and uninterrupted transition for existing clients and partners.

“The successful relationship between our firms has developed over many years of working together to support mutual clients in the Maryland market,” noted VaLogic Bio CEO Bill Robertson. “We are enthusiastic about permanently joining forces and further expanding our services and client base. Pat is well respected as a trusted advisor and leader and has deep national market knowledge.”

“We are excited about joining forces with VaLogic Bio,” commented Larrabee.

With the acquisition of Facility Logix, VaLogic Bio’s team now totals 72 employees, with offices in Texas and two offices in Maryland. This acquisition represents a significant step forward in VaLogic Bio’s unwavering commitment to simplifying compliance and ensuring peace of mind for life sciences organizations. By combining the strengths of both companies, VaLogic Bio is well-positioned to lead the industry in delivering innovative, efficient, and compliant solutions for life sciences facilities.

“I am very proud of our team’s capabilities and our portfolio of work over the past two decades,” said Larrabee. “And with the added capabilities of VaLogic Bio and the financial support of 424 Capital, we are poised to capture additional market share.”

For more information about the acquisition or to learn more about the services offered by VaLogic Bio, please visit www.valogicbio.com

Recent News

05/22/2026

BIO Statement on Veto of Prescription Drug Affordability Boards (PDAB) in VirginiaPatrick J. Plues, Senior Vice President of State Government Affairs & Affiliate Relations at the Biotechnology Innovation Organization (BIO) released the following statement on the veto of Prescription Drug Affordability Boards (PDAB) legislation in Virginia: “BIO applauds Governor Spanberger’s decision to veto SB 271 and HB 483 — legislation that would have established a Prescription Drug Affordability Board (PDAB) and imposed arbitrary price controls in Virginia. The Governor’s action recognized an important point: even well-intentioned healthcare policies must be carefully designed to avoid unintended consequences for patients, providers, employers, and Virginia’s innovation economy. “BIO is proud to represent biotechnology companies developing the next generation of life-changing medicines, including many in the Commonwealth. We believe policymakers play a critically important role in helping advance both patient access to treatments and the continued growth of the life sciences sector. “We look forward to working with the Governor’s Administration, the General Assembly, Virginia Bio and other stakeholders to advance practical, patient-centered policy solutions that improve affordability while preserving access to care and the innovation ecosystem patients depend on.”

Patrick J. Plues, Senior Vice President of State Government Affairs & Affiliate Relations at the Biotechnology Innovation Organization (BIO) released the following statement on the veto of Prescription Drug Affordability Boards (PDAB) legislation in Virginia: “BIO applauds Governor Spanberger’s decision to veto SB 271 and HB 483 — legislation that would have established a Prescription

05/21/2026

Virginia Bio Applauds Governor Spanberger’s Veto of SB 271 and HB 483

The Virginia Biotechnology Association (Virginia Bio) today expressed strong support for Governor Abigail Spanberger’s decision to veto Senate Bill 271 and House Bill 483, legislation that would have established a Prescription Drug Affordability Advisory Panel (PDAAP) in the Commonwealth. Virginia Bio and the Virginia Chamber of Commerce sent a joint letter to Governor Spanberger commending

05/21/2026

New Global Clinical Society to Bring Focused Ultrasound Into Mainstream Medicine

The Focused Ultrasound Foundation today announced the launch of the International Focused Ultrasound Society (IFUS), a new organization dedicated to advancing clinical practice and accelerating adoption of focused ultrasound – a revolutionary, noninvasive therapeutic technology. Established as a program of the Focused Ultrasound Foundation, IFUS aggregates and expands the Foundation’s activities related to clinical implementation